Role of Homoeopathic Medicine Staphysagria in Chronic Benign Prostatic Hyperplasia in the age group of 50-80 years

Role of Staphysagria in Case of 1st and 2nd Stage of Chronic Benign Prostatic Hyperplasia in the Age Group of 50-80 Years Assessed By International Prostate Symptom Score - Nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/079938

Enrollment

Registered

2025-02-04

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: HOMOEOPATHIC MEDICINE STAPHYSAGRIA: POTENCY VARIOUS DOSE AS PER NEED OF CASE FREQUENCY AS PER NEED OF CASE ROUTE OF ADMINISTRATION ORAL DURATION OF 8 MONTHS AS PER NEED OF CASE Control

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed case of 1st and 2nd stage of chronic benign prostatic hyperplasia Age group 50 TO 80 years International prostate symptom score value up to 19 Serum PSA level up to 4 ng mL Consent Participants are willing to provide written informed consent to participate in the study and can fill out the International Prostate Symptom Score IPSS A case showing symptom similarity with the staphysagria

Exclusion criteria

Exclusion criteria: Complete urinary retention for more than 24 hours Patients with significant comorbidities like chronic renal failure any malignancy uncontrolled diabetes type 2 and hypertension Patient taking medication from the allopathic ayurvedic and homeopathic systems of medicine for the 1st and 2nd stages of chronic benign prostatic hyperplasia Patients planning to undergo surgery within the next 6 months History of previous prostate surgery

Design outcomes

Primary

Measure	Time frame
IPSS SCORE SERUM PSA VALUE AND USG WHOLE ABDOMEN TO ASSESS REDUCTION IN SYMPTOMS OF CHRONIC BENIGN PROSTATIC HYPERPLASIATimepoint: IPSS SCORE SERUM PSA VALUE AND USG WHOLE ABDOMEN TO ASSESS REDUCTION IN SYMPTOMS OF CHRONIC BPH AT BASELINE AND END OF TREATMENT AND IF REQUIRED DURING THE TREATMENT	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDR JINAL PINAKINBHAI SHAH

SMT A J SAVLA HOMOEOPATHIC MEDICAL COLLEGE AND RESEARCH INSTITUTE

nisha.mehul.26@gmail.com9974342824

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026